Most importantly, future interventional studies should investigate whether inhibiting IFN-γ signaling can reduce intramuscular antibody production and improve clinical outcomes, particularly in myositis subtypes lacking effective treatments, such as IBM. Here, IFNG is linked to inclusion body myositis.